Pemetrexed and cisplatin is the name of a chemotherapy drug combination. It includes the drugs we list below, next to each drug we have how you pronounce the drug name in brackets. pemetrexed (peh-meh ...

Among these participants, 402 were assigned to vinorelbine plus cisplatin and 402 to pemetrexed plus cisplatin (intent-to-treat population). Sixteen patients did not start their assigned treatment (6 ...

This phase II study evaluated the efficacy and safety of pemetrexed plus cisplatin in advanced urothelial carcinoma. A total of 42 patients were enrolled (median age, 66 years; ECOG 0–1 ...

About the IMpower132 study IMpower132 is a Phase III, open-label, randomized study evaluating the efficacy and safety of TECENTRIQ plus chemotherapy (cisplatin or carboplatin and pemetrexed ...

Lymphedema After Breast Cancer: Incidence, Risk Factors, and Effect on Upper Body Function In advanced NSCLC, cisplatin/pemetrexed provides similar efficacy with better tolerability and more ...

The Santoro et al study is based on the results of an international EAP that provided patients with mesothelioma with access to single-agent pemetrexed or to cisplatin/pemetrexed or carboplatin ...

Nine patients with unresected stage III non-small-cell lung cancer were first given two cycles of chemotherapy, three weeks apart, with 500 mg/m2 of pemetrexed plus 75 mg/m2 of cisplatin.

The Appraisal Committee (appendix A) considered evidence submitted by the manufacturer of pemetrexed and reviews of these submissions by the Evidence Review Group (ERG; appendix B). 3.1 In the ...

43,44 The Mesothelioma Avastin plus Pemetrexed-Cisplatin Study (MAPS) showed that standard-of-care chemotherapy combined with bevacizumab, a monoclonal antibody targeting vascular endothelial ...

This study evaluated the efficacy and safety of ziv-aflibercept in combination with cisplatin and pemetrexed in non-small cell lung cancer (NSCLC). The study was closed prematurely because of ...

The Committee concluded that the gemcitabine/cisplatin combination was the principle comparator in UK clinical practice for the first-line treatment of NSCLC. 4.4 The Committee considered the evidence ...